RxDoctor Payments Data

Cassie Lemaster, APRN

Family · Collinsville, OKNPI 1528634573

Payments from drug & device makers

$2,313in general payments, 2019–2025

Across 115 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$763
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$486
  • Forte Bio-pharma LLC$220
  • Si-bone, Inc.$145
  • Averitas Pharma Inc.$114
  • Impel Pharmaceuticals Inc.$105
  • plus $479 from 11 others

What the payments were for

  • Food & beverage$2,313100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,313 in reported general payments places this provider in the 85th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$122,140
Medicare patients
159
Services billed
1,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide28$62,165
Buprenorphine103$20,739
MovantikNaloxegol Oxalate35$14,193
BelbucaBuprenorphine Hcl22$13,221
Lidocaine81$11,555
ZubsolvBuprenorphine Hcl/Naloxone Hcl35$8,288
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl132$7,141
Gabapentin230$2,190
Diclofenac Sodium73$2,174
Pregabalin138$1,905
Ibuprofen130$1,618
Tizanidine Hcl160$1,470
Lubiprostone24$1,342
Naloxone Hcl20$1,323
Tramadol Hcl ErTramadol Hcl17$1,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$486$62,16528 claims
Collegium Pharmaceutical, Inc.Belbuca$763$13,22122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,026 family providers in Oklahoma.

Other family in Collinsville

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →